Brain & Neuroprotection Peptides
Peptides researched for their ability to protect brain and nerve cells from damage, degeneration, and ischemia. Includes compounds targeting oxidative stress, inflammation, and excitotoxicity in neural tissue.
Other Categories
Related Categories
ARA-290
ARA-290 (Cibinetide): EPO-derived neuroprotective peptide. Covers innate repair receptor activation, sarcoidosis trials, dosing, and safety profile.
BPC-157
BPC-157: Gastric-derived healing peptide guide. Covers tissue repair mechanisms, gut-brain axis effects, tendon and GI healing research, and dosing.
Brimapitide
Brimapitide (AM-111): cell-penetrating JNK inhibitor peptide for sudden hearing loss. Phase 3 HEALOS trial results and intratympanic delivery mechanism.
Cebranopadol
Cebranopadol (GRT-6005): first-in-class dual NOP/opioid receptor agonist for pain. Phase 3 ALLEVIATE trials positive. FDA Fast Track for chronic low back pain.
Cerebrolysin
Cerebrolysin: Brain-derived peptide for stroke and TBI recovery. Covers neurotrophic mechanisms, approvals in 40+ countries, dosing, and safety data.
Davunetide
Davunetide (NAP): ADNP-derived octapeptide microtubule stabilizer. Covers PSP phase 2/3 trial failure, intranasal delivery, and ADNP syndrome research.
Dermorphin
Dermorphin: Potent frog-derived opioid peptide with 40x morphine selectivity. Covers mu-opioid mechanism, analgesic research, and safety concerns.
DSIP
DSIP: Delta sleep-inducing nonapeptide guide. Covers EEG sleep effects, stress hormone modulation, opioid withdrawal research, dosing, and safety.
EPO
EPO: FDA-approved hormone for anemia and red blood cell production. Covers erythropoiesis, neuroprotective research, dosing, and doping concerns.
Humanin
Humanin: 24-amino acid mitochondrial-derived peptide with anti-apoptotic and neuroprotective effects. Research in Alzheimer's, aging, and metabolic disease.
Klotho Peptides
Klotho peptides (KP1, KP6) are synthetic fragments of the alpha-klotho anti-aging protein. Research covers kidney fibrosis, diabetic nephropathy, FGF23/FGF21 signaling, cognitive enhancement, and neuroprotection in preclinical models.
Nomlabofusp
Nomlabofusp (CTI-1601): TAT-frataxin fusion protein for Friedreich ataxia. Phase 2 complete, BLA planned Q2 2026. First disease-modifying FA therapy.
Risuteganib
Risuteganib (Luminate/ALG-1001): first-in-class integrin-regulating peptide for dry AMD. Phase 2a showed 48% of patients gained 8+ ETDRS letters vs 7% sham.
Semax
Semax peptide guide: not FDA approved, but used in Russia since 2011. Covers BDNF upregulation, stroke recovery data, intranasal dosing, and safety risks.
Ziconotide
Ziconotide (Prialt): FDA-approved intrathecal peptide from cone snail venom. Blocks N-type calcium channels for severe chronic pain refractory to other therapies.
Zilucoplan
Zilucoplan (Zilbrysq): FDA-approved macrocyclic peptide C5 complement inhibitor for generalized myasthenia gravis. Daily SC self-injection by UCB.
Head-to-Head Comparisons
Detailed comparisons between brain & neuroprotection peptides covering mechanisms, efficacy, side effects, and research evidence.
Related Articles
Most Popular Therapeutic Peptides in 2026: 15 Ranked by Research Interest
The 15 most popular therapeutic peptides in 2026, ranked by clinical trial activity, search interest, and research community adoption. From semaglutide to BPC-157.
guideBest Peptides for Menopause Symptoms: 2026 Research Guide
Research guide covering peptides studied for menopause symptoms including hot flashes, bone loss, cognitive changes, skin aging, sleep disruption, and hormonal regulation.
research-reviewFinnrick Analytics Review: Transparency Concerns and Conflicts of Interest (2026)
Is Finnrick Analytics trustworthy? We examine COI gaps, vendor pay-for-play, 15% lab discrepancies, and their astroturfing job listing. Full analysis.
research-reviewJanoshik Analytical Review: The Story Behind the Gray Market's Most Trusted Peptide Testing Lab
Who is Janoshik? We profile the Czech lab behind the gold standard in peptide testing. Founder Peter Magic, pricing, controversies, and community trust.
newsCompounding Pharmacy Peptide Access: 2026 Regulatory Changes
An overview of the 2026 regulatory landscape for compounded peptides, covering FDA enforcement actions, the impact on semaglutide and tirzepatide compounding, 503A and 503B pharmacy rules, and what patients and providers need to know about peptide access.
guideHow to Choose Your First Peptide: A Decision Framework by Goal
A comprehensive decision framework to help beginners identify the right peptide for their goals. Maps 10 health categories to specific peptide recommendations with evidence levels, administration routes, and regulatory context.
Research Tools
Use our interactive tools to explore brain & neuroprotection peptides further.